AbCellera Biologics Inc vs Procter & Gamble Co — how do they compare? AbCellera Biologics Inc trades at $9.07 (market cap $2.85B), while Procter & Gamble Co trades at $144.61 (market cap $340.39B). The key difference: Procter & Gamble Co is far larger — about 119.4× AbCellera Biologics Inc's market cap, and Procter & Gamble Co pays a 2.97% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | PG | |
|---|---|---|
Market Cap | $2.85B | $340.39B |
Sector | Health | Consumer Staples |
52-Week High | $9.76 | $167.18 |
52-Week Low | $2.78 | $138.10 |
Enterprise Value | $2.45B | $366.23B |
Volume | — | 6,423,436 |
Dividend Yield | — | 2.97% |
Signals from Pluang's Aura AI — not financial advice
ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.
The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.
Procter & Gamble (PG) trades at $146.38, up 0.42% on the day, with a bearish technical signal but strong fundamentals including a net income margin of 18.44% and consistent earnings beats. The company maintains robust cash flow from operations of $17.82B in 2025 and a dividend track record, with a recent partnership with the WNBA signaling strategic brand expansion. Valuation ratios like P/E of 22.12 and P/S of 4.08 reflect a premium to peers amid modest revenue growth.
PG offers stability with high profitability and dividend reliability, but premium valuation and soft demand outlook pose near-term risks. Analyst consensus is bullish with a $161.20 price target, though technical indicators suggest caution. Key risks include economic sensitivity and competitive pressures, while institutional holdings show mixed sentiment.
Trailing returns across standard periods
Latest headlines on both assets
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →